A study to investigate the efficacy and safety of elecoglipron in Asian participants with obesity or overweight with or without type 2 diabetes mellitus - Elecoglipron

Inclusion Criteria

• Inclusion Criteria:
• - Adult participant aged 18 years or older at the time of informed consent.
• - Body mass index (BMI) at screening of:
• -28 kg/m^2 or higher, or
• -24 kg/m^2 to less than 28 kg/m^2 with at least 1 weight-related comorbidity.
• - Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
• - History of at least 1 self-reported unsuccessful dietary effort to lose body weight.
• - Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening.
• Exclusion Criteria:
• - Any of the following medical history, laboratory values, or complications related to diabetes:
• -T1DM
• -HbA1c ≥ 10% (86 mmol/mol) at the screening visit
• -Currently receiving, or anticipated to receive, therapeutic
• intervention for diabetic retinopathy and/or macular edema.
• -Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
• - History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis.
• - History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2.